Phase 2
ZYESAMI is intended to block the replication of SARS-CoV-2 in the ATII cell, as well as cytokine synthesis, thereby relieving respiratory distress. It is the only treatment in development that targets these ATII cells, and if approved, would be the first drug on the market for COVID-19 patients critically ill with respiratory failure.
Tryp and Dr. Miller have begun designing a Phase 2a open-label, exploratory clinical study utilizing TRP-8802 in patients suffering from rare and orphan over-eating disorders.
Veru announced positive results from its Phase II trial of its VERU-111 compared to placebo in hospitalized patients at high risk for Acute Respiratory Distress Syndrome (ARDS) from COVID-19.
While the space is just beginning to emerge, therapies for long-haul COVID-19 patients are still very much an unmet need.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 9, 2021.
Shares of Avrobio were up nearly 20% in premarket trading after the company posted positive clinical data from its gene therapy trials in three different rare lysomal diseases, Fabry, Gaucher type 1 and cystinosis.
Over the course of 2020, Sanofi saw significant growth in its specialty care sales primarily driven by its blue-chip asset, Dupixent, as well as an increase in vaccine sales that were driven by demand for differentiated influenza vaccines, the company announced in its year-end financial report.
It was a busy week for clinical trial updates. Here’s a look.
Roche is closing out its fourth-quarter with some house cleaning. The Swiss pharma giant announced in its earnings report that it was terminating studies of several mid- and late-stage assets, including two late-stage breast cancer programs.
As the therapy “did not achieve proof-of-concept” and failed to provide benefit in this study, the development of the drug has been discontinued.
PRESS RELEASES